Amendment to the Specification

- Please replace the paragraph beginning at page 1, line 2 as follows:

This application is a continuation of U.S. Patent Application Serial No. 08/942,867, filed October 2, 1997, now abandoned, which is a continuation-in-part of U.S. Patent Application Serial No. 08/656,984, filed June 6, 1996, ~~and currently pending~~ now U.S. Pat. No. 5,753,502, which is a continuation-in-part of U.S. Patent Application Serial No. 08/481,130, filed June. 7, 1995, ~~and currently pending,~~ now U.S. Pat. No. 5,702,917, which is a continuation-in-part of U.S. Patent Application Serial No. 08/245,295, filed May 18, 1994, ~~and currently pending,~~ now U.S. Pat. No. 5,700,658, which in turn is a continuation-in-part of U.S. Patent Application Serial No. 08/102,852, filed August 5, 1993 and now abandoned, which in turn is a continuation-in-part of U.S. Patent Application Serial No. 08/009,266, filed January 22, 1993 and now abandoned, which is a continuation-in-part of U.S. Patent Application Ser. No. 07/894,061, filed June 5, 1992 and now abandoned, which is a continuation-in-part of U.S. Patent Application Serial No. 07/889,724, filed May 26, 1992 and now abandoned, which is a continuation-in-part of U.S. Patent Application Serial No. 07/827,689, filed January 27, 1992 and now abandoned.

- Please replace the paragraph beginning at page 4, line 15 as follows:

Despite the fundamental insights into cell adhesion phenomena which have been gained by the identification and characterization of intercellular adhesion proteins such as ICAM-1 and lymphocyte interactive integrins such as LFA-1, the picture is far from complete. It is generally believed that numerous other proteins are involved in inflammatory processes and in targeted lymphocyte movement throughout the body. For example, ~~U.S. Patent Application Serial Nos. 07/827,689, 07/889,724, 07/894,061 and 08/009,266 and corresponding~~ published PCT Application WO 93/14776 (published August 5, 1993) discloses ~~disclose~~ the cloning and expression of an ICAM-Related protein, ICAM-R. The disclosures of ~~these~~ this applications ~~are~~ is specifically incorporated by reference herein and the DNA and amino acid sequences of ICAM-R are set out in SEQ ID NO. 4 herein. This new ligand has been found to be expressed on human lymphocytes, monocytes and granulocytes.

- Please replace the paragraph beginning at page 11, line 21 as follows:

The disclosures of parent U.S. Patent Application Serial No. 08/102,852, filed August 5, 1993, now abandoned, and corresponding to U.S. Patent 6,087,130, are specifically incorporated by reference. The examples of that application address, inter alia: design and construction of oligonucleotide probes for PCR amplification of ICAM related DNAs; use of the probes to amplify a human genomic fragment homologous to, but distinct from DNAs encoding ICAM-1 and ICAM-2; screening of cDNA libraries with the genomic fragment to isolate additional ICAM-R coding sequences; screening of cDNA libraries to isolate a full length human cDNA sequence encoding ICAM-R; characterization of DNA and amino acid sequence information for ICAM-R, especially as related to ICAM-1 and ICAM-2; development of mammalian host cells expressing ICAM-R; assessment of indications of ICAM-R participation in adhesion events involving CD18-dependent and CD18-independent pathways; inhibition of cell adhesion to ICAM-R by ICAM-R-derived peptides; expression of variants of ICAM-R; preparation and characterization of anti-ICAM-R antibodies and fragments thereof; mapping of ICAM-R epitopes recognized by anti-ICAM-R monoclonal antibodies; assessment of the distribution and biochemical characterization of ICAM-R and RNA encoding the same; assessment of ICAM-R in homotypic cell-cell adhesion and immune cell activation/proliferation; characterization of ICAM-R monoclonal antibodies; and assessment of differential phosphorylation and cytoskeletal associations of the cytoplasmic domain of ICAM-R. Also disclosed was the identification of a rodent ICAM-encoding DNA that, at the time, appeared to be the rat homolog of human ICAM-R, and the use of this DNA to construct and express DNAs encoding glutathione-S-transferase fusion proteins. The detailed description of how this rodent DNA was identified can be found in the ~~parent application~~ related disclosure of (~~U.S.S.N. 08/102,852~~ U.S. Patent 6,087,130) in Example 6, and is reproduced herein as Example 1. As more of the rodent ICAM-coding sequence was identified, it became apparent that the rodent ICAM DNA did not encode a rat species homolog of human ICAM-R, but, in fact, encoded a novel ICAM polypeptide, herein named ICAM-4. In order to appreciate the events which

led to the identification of ICAM-4, a chronology is provided which is followed by a detailed description of the invention.

- Please replace the paragraph beginning at page 12, line 2 as follows:

A first rodent genomic ICAM-4 sequence was identified which encoded a region homologous to domain 2 (herein SEQ ID NO: 3~~, and SEQ ID NO: 23 of U.S.S.N. 08/102,852~~) of human ICAM-R (herein as SEQ ID NO: 4). A second, overlapping genomic DNA (herein SEQ ID NO: 5~~, and SEQ ID NO: 26 of U.S.S.N. 08/102,852~~) was also identified which encoded both the domain 2 region of SEQ ID NO: 3, and sequences for ICAM-1. Using SEQ ID NO: 3 as a probe, a rodent spleen cDNA (herein SEQ ID NO: 6~~, and SEQ ID NO: 25 in U.S.S.N. 08/102,852~~) was identified which encoded domains 2 through 5 as well as a fifth domain not previously observed as an ICAM domain. At this time, these newly identified rodent DNAs appeared to encode a rodent homolog of human ICAM-R, however alignment of 3′ regions of these DNAs with other ICAMs proved difficult.

- Please replace the paragraph beginning at page 15, line 6 as follows:

A first genomic clone encoding a rat ICAM-related domain 2 was identified that was determined to be homologous to domain 2 regions in other ICAM family members (see for example, Table 1 of ~~U.S. Patent Application Serial No. 08/102,852~~ U.S. Patent 6,087,130), yet was distinct from the previously reported nucleotide sequences for rat ICAM-1 [Kita, et al., Biochem.Biophys.Acta 1131:108-110 (1992)] or mouse ICAM-2 [Xu, et al., J.Immunol. 149:2560-2565 (1992)]. The nucleic acid and deduced amino acid sequences for this clone were disclosed in the co-pending parents to the present application as purportedly variant forms of rat ICAM-R and were set forth as SEQ ID NOs: 23 and 24, respectively, in U.S.S.N. 08/102,852. Herein, these same sequences are set out in SEQ ID NOs: 3 and 13, respectively.